1.
Charcot-Marie-Tooth Disease with Myelin Protein Zero Mutation Presenting as Painful, Predominant Small-Fiber Neuropathy.
Int J Mol Sci
; 25(3)2024 Jan 29.
Article
En
| MEDLINE | ID: mdl-38338934
2.
Are novel outcome measures for Charcot-Marie-Tooth disease sensitive to change? The 6-minute walk test and StepWatch™ Activity Monitor in a 12-month longitudinal study.
Neuromuscul Disord
; 29(4): 310-316, 2019 04.
Article
En
| MEDLINE | ID: mdl-30926199
3.
Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients.
Neuromuscul Disord
; 24(11): 1003-17, 2014 Nov.
Article
En
| MEDLINE | ID: mdl-25085517
4.
Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.
Lancet Neurol
; 10(4): 320-8, 2011 Apr.
Article
En
| MEDLINE | ID: mdl-21393063
5.
Disease course of Charcot-Marie-Tooth disease type 2 and comorbidity.
Arch Neurol
; 61(9): 1470; author reply 1470, 2004 Sep.
Article
En
| MEDLINE | ID: mdl-15364699
6.
A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27].
Pharmacol Res
; 54(6): 436-41, 2006 Dec.
Article
En
| MEDLINE | ID: mdl-17029975
7.
Sensory manifestations in Charcot-Marie-Tooth disease.
J Peripher Nerv Syst
; 9(1): 7-14, 2004 Mar.
Article
En
| MEDLINE | ID: mdl-14871449
8.
Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV.
Neurology
; 68(18): 1543-4; author reply 1544, 2007 May 01.
Article
En
| MEDLINE | ID: mdl-17470762
9.
Antiviral therapy for cryoglobulinemic neuropathy: comment on the article by Saadoun et al.
Arthritis Rheum
; 56(8): 2810; author reply 2810-1, 2007 Aug.
Article
En
| MEDLINE | ID: mdl-17665398